PAHC earnings / call / takeaways

PAHC earnings call: key takeaways

What PAHC said on its earnings call of November 4, 2026: results against expectations, what changed since last quarter, guidance and the questions analysts pressed on.

By Lician·November 4, 2026·AI-generated from the call transcript and Lician data

Fibro Animal Health Corporation reported adjusted EPS of $3.41 to $3.59 for fiscal 2027, in line with the previously provided guidance (5:45)
The company maintained its full-year guidance despite a strong Q1 performance. (12:52)

Results vs expectations

Metric	Consensus	Reported	Result
EPS	$0.79	–	–
Revenue	$383.0M	–	–

EPS basis: Provider EPS (EODHD), not yet checked against the SEC

What changed since last quarter

The company maintained its fiscal 2027 guidance for net sales, adjusted EBITDA, and EPS, despite a better-than-expected Q1 performance. (12:52)
The CFO mentioned that some costs were shifted from Q1 to Q2, which could affect future quarters. (12:52)
The CEO noted that the company is optimistic about the long-term approval of Virginia Mites in Brazil but remains cautious about timing. (17:42)

Guidance

Metric	This call	Previous call
EBITDA	Adjusted EBITDA of $258 to $268 million for fiscal 2027 (12:52)	not captured
Net income	Adjusted net income of $140 to $147 million for fiscal 2027 (12:52)	not captured

What analysts pressed on

Concerns about the timing and approval of Virginia Mites in Brazil. (15:50)
Inquiry into the durability of growth in the MFA portfolio and the impact of Zoetis integration. (16:10)

In their words

We're carrying more inventory than we need, and bringing it down this year is a priority. Donnie Bantime (5:45)

Read the full transcript with the AI summary, or listen on the company's official webcast.

Every past call in full and transcript search come with Lician Pro.

Written by AI from the automatic transcript of the company's public webcast and Lician's earnings data. Each sentence cites the passage it comes from, and a sentence with a figure that is not in its sources was removed. Not investment advice.